Last reviewed · How we verify
NCT00002019
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome
NA trial testing Amphotericin B, Lipid-based in Meningitis, Cryptococcal. Completed.
Quick facts
| Lead sponsor | Liposome |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Primary purpose | treatment |
| Sites | 19 locations across United States |
Drugs / interventions tested
- Amphotericin B, Lipid-based — full drug profile →
- Amphotericin B (AMPHOTERICIN B) — full drug profile →
Conditions studied
- Meningitis, Cryptococcal — all drugs for Meningitis, Cryptococcal →
- HIV Infections — all drugs for HIV Infections →
Sponsor
Liposome — full company profile →
Who can join
18 and older, any sex, with Meningitis, Cryptococcal or HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.
Botero Aguirre JP, Restrepo Hamid AM. · · 2015 · cited 56× · PMID 26595825 · DOI 10.1002/14651858.cd010481.pub2 -
"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".
Taïeb J, Benhaim L, Laurent Puig P, Le Malicot K, et al · · 2020 · cited 31× · PMID 32482534 · DOI 10.1016/j.dld.2020.04.010 -
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment.
Crisafulli G. · · 2025 · cited 8× · PMID 39858618 · DOI 10.3390/genes16010071 -
From Early Detection To Advanced Therapies: How Circulating Tumor DNA Is Transforming the Care of Colorectal Cancer.
Yee EJ, McCarter MD, Vogel JD, Schulick RD, et al · · 2025 · cited 1× · PMID 41182655 · DOI 10.1007/s11912-025-01725-8 -
Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B.
Boudier A, Mammari N, Lamouroux E, Duval RE. · · 2023 · cited 1× · PMID 37887244 · DOI 10.3390/antibiotics12101543 -
Microencapsulation Techniques in HIV Pediatric Formulations: Advances and Future Outlook.
Okafor NI. · · 2024 · PMID 39421019 · DOI 10.1155/2024/5081655
Verify or expand the search:
- PubMed search for NCT00002019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00002019 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liposome
- Last refreshed: 23 June 2005
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing